Chediak-Higashi syndrome (CHS) is an extremely rare inherited disorder that disrupts immune function, pigmentation, and blood clotting. Fewer than 500 cases have ever been reported worldwide. It typically appears in infancy or early childhood, and without treatment, most children develop a life-threatening inflammatory crisis before age 10.
What Causes It
CHS results from mutations in the LYST gene, which provides instructions for a protein that helps transport materials into and out of lysosomes. Lysosomes are small structures inside cells that act as recycling centers, breaking down bacteria, toxins, and worn-out cell parts. When the LYST protein doesn’t work properly, lysosomes become abnormally large and lose their ability to function normally.
This single genetic defect ripples across multiple cell types. In immune cells, the oversized lysosomes prevent the cell from effectively killing bacteria. In pigment-producing cells called melanocytes, related structures called melanosomes also become giant and malfunction, leading to unusually light skin and hair. In platelets (the cells responsible for blood clotting), tiny storage compartments called dense granules are severely depleted, causing bleeding problems. The syndrome is inherited in an autosomal recessive pattern, meaning a child must receive a defective copy of the gene from both parents.
How It Affects Appearance
One of the earliest and most visible signs is partial albinism. Children with CHS typically have very fair skin and light-colored hair that often carries a distinctive silvery or metallic sheen. Their eyes are also affected: reduced pigment leads to light sensitivity, involuntary rapid eye movements (nystagmus), and decreased visual sharpness. These features are often what first prompts a parent or pediatrician to investigate further.
Immune System Breakdown
The immune problems in CHS are the most dangerous part of the condition. Children experience frequent, severe bacterial infections starting in infancy, particularly of the skin, lungs, and respiratory tract. Two specific types of immune cells are impaired. Neutrophils, which are the body’s first responders to bacterial invasion, are both reduced in number and sluggish in function. Natural killer (NK) cells, which normally patrol for virus-infected cells, are present in normal numbers but largely inactive. Studies have shown that CHS patients have normal percentages of NK cells capable of binding to targets, but the proportion of those cells that can actually kill is significantly reduced.
This combination of defects leaves children highly vulnerable to infections that a healthy immune system would handle easily.
Bleeding Tendencies
People with CHS bruise easily and bleed longer than expected from minor cuts or injuries. The cause traces back to those same oversized, malfunctioning cellular compartments. Platelets rely on tiny dense granules packed with signaling molecules (ATP, ADP, serotonin, and calcium) to trigger normal clotting. In CHS, these granules are severely depleted. Studies of patients’ platelets consistently show greatly decreased levels of all four dense granule components and abnormal clumping behavior. This is classified as a storage pool deficiency, a well-documented feature of the syndrome.
The Accelerated Phase
The most feared complication of CHS is progression to what’s called the accelerated phase, a form of hemophagocytic lymphohistiocytosis (HLH). This occurs in 50 to 85 percent of patients with the classic form of the disease. During HLH, the immune system spirals into an uncontrolled inflammatory state: white blood cells begin infiltrating and damaging the liver, spleen, lymph nodes, and other organs. It is often triggered by a viral infection.
The accelerated phase is characterized by high fevers, dangerously low blood cell counts affecting all cell lines, and massive organ enlargement, particularly of the spleen and liver. Without aggressive treatment, this phase is fatal. Even with treatment, it remains very difficult to control. The underlying mechanism likely involves the dysfunctional NK cells, which cannot properly clear virus-infected cells, leading to a feedback loop of escalating inflammation.
How It’s Diagnosed
The diagnostic hallmark of CHS is the presence of giant granules inside white blood cells, visible under a standard microscope on a peripheral blood smear. These abnormally large inclusions are present in circulating white blood cells and their precursors in the bone marrow. They contain digestive enzymes, confirming they are oversized lysosomes. A pathologist can identify them relatively quickly, making this one of the more straightforward rare disease diagnoses once CHS is suspected.
Additional lab findings typically include low neutrophil counts and elevated antibody levels (hypergammaglobulinemia). Genetic testing of the LYST gene confirms the diagnosis and can help predict severity. Nonsense or frameshift mutations, which essentially destroy the protein entirely, are associated with the classic, more severe childhood form. Milder missense mutations can lead to a less severe presentation that may not be recognized until adolescence or adulthood.
Treatment and Outlook
The only treatment that corrects the underlying immune defect is a bone marrow transplant (hematopoietic stem cell transplant). This replaces the patient’s defective immune cells with healthy donor cells. Transplant outcomes have improved over time. In one reported series of eight patients who underwent transplant, six survived. Patients transplanted before entering the accelerated phase generally do better, and reduced-intensity conditioning regimens (which use lower doses of preparatory chemotherapy) have shown promise as a less toxic alternative for patients without active HLH.
A successful transplant corrects the immune dysfunction and bleeding problems but does not reverse the pigmentation changes or vision issues, since those involve non-blood cells that the transplant doesn’t replace. It also does not prevent neurological problems that may develop over time, including progressive nerve damage. For patients who survive into adulthood, whether through transplant or because they have a milder genetic variant, neurological decline can become the primary long-term challenge.
There is no racial or ethnic predisposition to CHS. The condition affects all populations equally. Because symptoms can vary widely depending on the specific mutation, milder cases are likely underdiagnosed. The disease typically presents before age five, but atypical forms can remain unrecognized for years. Early recognition matters enormously, since transplant before the accelerated phase offers the best chance at long-term survival.